-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Baricitinib is a daily oral selectivity, reversible JAK1 and JAK2 inhibitor and is currently clinically used in the treatment of a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), severe spinalitis (AS), psoriasis, a specific dermatitis, systemic lupus erythematosus, ulcerative enteritis (UC) and more.
a recent study published in Ann Rheum Dis, a leading journal of rheumatology, assessed the incidence of infection with barictini for the treatment of active rheumatoid arthritis (RA).
study summarized a comprehensive database (including 8 3/2/1b clinical trials and 1 long-term extended trial (LTE)) infections by April 1, 2017.
"all-bari-RA" analysis was included in all patients who had received Barictini treatment.
used placebo comparisons based on six studies using 4 mg barektini and placebo (24 weeks in total), and 4 trials used 2 mg Barricktinini (placebo-control group).
was conducted on a dose-reaction basis based on four studies using 2mg and 4mg Barricktini, including LTE data (2-4mg).
results were as follows: 3,492 patients were treated with barictini, for a total of 7,860 patients -years (PY) (2.6 years, up to a period of 6.1 years).
incidence of infections requiring emergency treatment in the Baricinib group was higher than that of placebos (adjusted incidence (IR)/100 PY: placebo 75.9, 2mg 84.0 (p not significant), 4 mg 88.4 (p.001).)
baricinide group had a similar incidence of severe infection with placebo and remained stable over time (incidence 3.0/100 PY).
11 cases of tuberculosis (incidence 0.1/100 PY), all occurred in endemic areas where 4 mg was used.
the incidence of herpes with shingles (HZ) was higher than that of placebos (placebo 1.0/100 PY, 2mg 3.1 (no significant), 4mg 4.3 (p.01)," and the incidence remained high and remained stable over time (3.3).
infections, including multiple HZ, were not common in the Barricktini trial (0.5/100 PY).
the study showed an increased incidence of infections, including shingles, in RA patients treated with Barricktini that required urgent treatment.
this is consistent with Barricktini's immunomodating patterns.
.
